- Home
- VTAK vs PRFX Comparison
VTAK vs PRFX Comparison
Compare VTAK & PRFX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VTAK
- PRFX
- Stock Information
- Founded
- VTAK 2002
- PRFX 2007
- Country
- VTAK United States
- PRFX Israel
- Employees
- VTAK N/A
- PRFX N/A
- Industry
- VTAK Medical/Dental Instruments
- PRFX Biotechnology: Pharmaceutical Preparations
- Sector
- VTAK Health Care
- PRFX Health Care
- Exchange
- VTAK Nasdaq
- PRFX Nasdaq
- Market Cap
- VTAK 3.1M
- PRFX 2.9M
- IPO Year
- VTAK 2018
- PRFX 2020
- Fundamental
- Price
- VTAK $0.24
- PRFX $1.38
- Analyst Decision
- VTAK
- PRFX Hold
- Analyst Count
- VTAK 0
- PRFX 1
- Target Price
- VTAK N/A
- PRFX N/A
- AVG Volume (30 Days)
- VTAK 41.3M
- PRFX 182.3K
- Earning Date
- VTAK 08-13-2025
- PRFX 08-14-2025
- Dividend Yield
- VTAK N/A
- PRFX N/A
- EPS Growth
- VTAK N/A
- PRFX N/A
- EPS
- VTAK N/A
- PRFX N/A
- Revenue
- VTAK $481,000.00
- PRFX N/A
- Revenue This Year
- VTAK $822.86
- PRFX N/A
- Revenue Next Year
- VTAK $168.42
- PRFX N/A
- P/E Ratio
- VTAK N/A
- PRFX N/A
- Revenue Growth
- VTAK 9.57
- PRFX N/A
- 52 Week Low
- VTAK $0.16
- PRFX $1.25
- 52 Week High
- VTAK $4.76
- PRFX $16.63
- Technical
- Relative Strength Index (RSI)
- VTAK 45.34
- PRFX 33.47
- Support Level
- VTAK $0.22
- PRFX $1.37
- Resistance Level
- VTAK $0.25
- PRFX $1.48
- Average True Range (ATR)
- VTAK 0.02
- PRFX 0.10
- MACD
- VTAK -0.01
- PRFX 0.00
- Stochastic Oscillator
- VTAK 11.79
- PRFX 25.59
About VTAK Catheter Precision Inc.
Catheter Precision Inc is engaged in design, manufacture and sale of new and innovative medical technologies primarily focused in the field of cardiac electrophysiology, or EP. The Company's primary product is the View into Ventricular Onset System (VIVO or VIVO System), which is a non-invasive imaging system that offers 3D cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures. The VIVO system has achieved a CE Mark allowing it to be commercialized in the European Union and has been placed at several hospitals in Europe. Its newest product, the Surgical Vessel Closing Pressure Device (LockeT), is a suture retention device indicated for wound healing by distributing suture tension.
About PRFX PainReform Ltd.
PainReform Ltd is a clinical-stage specialty pharmaceutical company. It is focused on the reformulation of established therapeutics. The company's product PRF-110 is based on the local anesthetic ropivacaine, targeting the post-operative pain relief market. PRF-110 is an oil-based, viscous, clear solution that is deposited directly into the surgical wound bed before closure to provide localized and extended post-operative analgesia.